Celyad Oncology SA American Depositary Shares
CYAD
CYAD was delisted on the 18th of May, 2023.
8 hedge funds and large institutions have $11.4M invested in Celyad Oncology SA American Depositary Shares in 2022 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 4 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 8 → 8 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
32% less capital invested
Capital invested by funds: $16.8M → $11.4M (-$5.41M)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$1.68K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$35K |
| 2 |
Wells Fargo
San Francisco,
California
|
-$7.5K |
| 3 |
HF
HRT Financial
New York
|
-$7.03K |
| 4 |
Morgan Stanley
New York
|
-$200 |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$12 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FIG
1
Fortress Investment Group
New York
| $11.2M | – | – | – |
|
|
HF
2
HRT Financial
New York
| $57K | -$7.03K | -3,512 | -10% |
|
|
3
Morgan Stanley
New York
| $34K | -$200 | -100 | -0.5% |
|
|
4
Wells Fargo
San Francisco,
California
| $24K | -$7.5K | -3,750 | -21% |
|
|
5
UBS Group
Zurich,
Switzerland
| $7K | -$12 | -6 | -0.1% |
|
6
National Bank of Canada
Montreal,
Quebec, Canada
| $5K | – | – | – |
|
7
Osaic Holdings
Scottsdale,
Arizona
| $3K | – | – | – |
|
|
CS
8
Credit Suisse
Zurich,
Switzerland
| $1K | +$1.68K | +838 | New |
|
|
9
Citadel Advisors
Miami,
Florida
| – | -$35K | -14,598 | Closed |
|
CYAD Hedge Fund Activity: Q2 2022 in Review
8 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Celyad Oncology SA American Depositary Shares (CYAD) for Q2 2022, worth a combined $11.4M — down 32% from $16.8M a quarter earlier.
Fund positioning in CYAD was balanced in Q2 2022: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 4 trimmed.
The largest buyer was Credit Suisse, opening a new position worth an estimated $1.68K. The largest seller was Citadel Advisors, exiting entirely with an estimated $35K sold.
- 8 institutional investors held Celyad Oncology SA American Depositary Shares (CYAD) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $11.4M of Celyad Oncology SA American Depositary Shares stock for Q2 2022, down 32% quarter-over-quarter.
- 1 fund opened new Celyad Oncology SA American Depositary Shares positions in Q2 2022 and 1 closed out, a net change of 0 holders.
- The largest Celyad Oncology SA American Depositary Shares buyer in Q2 2022 was Credit Suisse, an estimated $1.68K added.
- The largest Celyad Oncology SA American Depositary Shares seller in Q2 2022 was Citadel Advisors, an estimated $35K sold.
Based on aggregated 13F filings for Q2 2022.